ArticleClinical pharmacology and therapeutics2016
Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.
Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Assessing the reproducibility of American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) arthroplasty studies.Journal of orthopaedic surgery and research · 2025Pooled it
- Quality of reporting of drug exposure in pharmacoepidemiological studies.Pharmacoepidemiology and drug safety · 2020Pooled it
- Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.Annals of internal medicine · 2019 · on this mapPooled it
- Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.BMJ open diabetes research & care · 2025Trial
- Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.Clinical pharmacology and therapeutics · 2023Trial
- Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19.Scientific reports · 2023Trial
- Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy.Neurology and therapy · 2026Article
- Anticoagulation Outcomes in Nursing Home Residents With Atrial Fibrillation and ADL Disability.JAMA network open · 2026Article
- The replicability of real-world evidence for the surgical treatment of proximal humeral fractures in older patients evaluated using sceptical p-value.Scientific reports · 2026Observational
- Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study.Alzheimer's research & therapy · 2026Article
- Bleeding Risk With Apixaban Versus Rivaroxaban: A Reference Trial Emulation Predicting the Results of COBRRA-VTE and COBRRA-AF Using US Health Care Claims.Circulation. Population health and outcomes · 2026Observational
- Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease.JAMA network open · 2026Article
- Article
- Article
- Article
- Improving machine-learning development in allergology: bridging the gap between open-access and cohort-based databases.Current opinion in allergy and clinical immunology · 2026Review
- Use of Incurred Sample Reproducibility Data to Support Long Term Stability of Therapeutic Antibodies in Clinical Bioanalytical Methods.AAPS PharmSciTech · 2026Article
- Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.Scientific reports · 2026Article
- Sociodemographic differences in discontinuation of high-risk medications: a retrospective cohort study.npj aging · 2025Article
- Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation.BMJ (Clinical research ed.) · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The scientific community and decision-makers are increasingly concerned about transparency and reproducibility of epidemiologic studies using longitudinal healthcare databases. We explored the extent to which published pharmacoepidemiologic studies using commercially available databases could be reproduced by other investigators. We identified a nonsystematic sample of 38 descriptive or comparative safety/effectiveness cohort studies. Seven studies were excluded from reproduction, five because of violation of fundamental design principles, and two because of grossly inadequate reporting. In the remaining studies, >1,000 patient characteristics and measures of association were reproduced with a high degree of accuracy (median differences between original and reproduction <2% and <0.1). An essential component of transparent and reproducible research with healthcare databases is more complete reporting of study implementation. Once reproducibility is achieved, the conversation can be elevated to assess whether suboptimal design choices led to avoidable bias and whether findings are replicable in other data sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.